Targeting ENaC as a molecular suspect in cystic fibrosis

Current Drug Targets

Volumn 16, Issue 9, 2015, Pages 951-957

  Bangel Ruland, Nadine ^a   Tomczak, Katja ^a   Weber, Wolf Michael ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Amiloride; ASOs; CFTR; Cystic fibrosis; ENaC; SiRNA

Indexed keywords

AMILORIDE; ANTISENSE OLIGONUCLEOTIDE; BENZAMIL; CHLORIDE ION; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DEGENERIN SODIUM CHANNEL; EPITHELIAL SODIUM CHANNEL; FOMIVIRSEN; MESSENGER RNA; MIPOMERSEN; PHENAMIL; SMALL INTERFERING RNA; CFTR PROTEIN, HUMAN; EPITHELIAL SODIUM CHANNEL BLOCKING AGENT; MOLECULAR LIBRARY; SODIUM;

ARTICLE; CHEMOTHERAPY; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; GENE MUTATION; HUMAN; LUNG DISEASE; MOLECULARLY TARGETED THERAPY; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RNA INTERFERENCE; STOICHIOMETRY; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; GENETICS; METABOLISM; MOLECULAR LIBRARY; PHARMACOLOGY; THERAPEUTIC USE;

AMILORIDE; CLINICAL TRIALS AS TOPIC; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; EPITHELIAL SODIUM CHANNEL BLOCKERS; EPITHELIAL SODIUM CHANNELS; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; RNA, SMALL INTERFERING; SMALL MOLECULE LIBRARIES; SODIUM;

EID: 84942123413     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450116666141212101626     Document Type: Article

References (72)

1. Boucher RC. Evidence for airway surface dehydration as the initiating event in CF airway disease. J Intern Med 2007; 261(1): 5-16.
2. Knowles MR, Stutts MJ, Spock A, Fischer N, Gatzy JT, Boucher RC. Abnormal ion permeation through cystic fibrosis respiratory epithelium. Science 1983; 221(4615): 1067-70.
3. Boucher RC, Stutts MJ, Knowles MR, Cantley L, Gatzy JT. Na+ transport in cystic fibrosis respiratory epithelia. Abnormal basal rate and response to adenylate cyclase activation. J Clin Invest 1986; 78(5): 1245-52.
4. Boucher RC, Cotton CU, Gatzy JT, Knowles MR, Yankaskas JR. Evidence for reduced Cl-and increased Na+ permeability in cystic fibrosis human primary cell cultures. J Physiol (Lond) 1988; 405: 77-103.
5. Kunzelmann K, Kathöfer S, Greger R. Na+ and Cl-conductances in airway epithelial cells: increased Na+ conductance in cystic fibrosis. Pflügers Arch -Europ J Physiol 1995; 431: 1-9.
6. Rückes-Nilges C, Weber U, Lindemann H, Münker G, Clauss W, Weber W-M. Minor role of Cl-secretion in non-cystic fibrosis and cystic fibrosis human nasal epithelium. Cell Physiol Biochem 1999; 9: 1-11.
7. Bangel N, Dahlhoff C, Sobczak K, Weber WM, Kusche-Vihrog K. Upregulated expression of ENaC in human CF nasal epithelium. J Cyst Fibros 2008; 7(3): 197-205.
8. Mall M, Grubb BR, Harkema JR, O'Neal WK, Boucher RC. Increased airway epithelial Na+ absorption produces cystic fibrosislike lung disease in mice. Nat Med 2004; 10(5): 487-93.
9. Collawn JF, Lazrak A, Bebok Z, Matalon S. The CFTR and ENaC debate: how important is ENaC in CF lung disease? Am J Physiol Lung Cell Mol Physiol 2012; 302(11): L1141-L1146.
10. Zhou Z, Duerr J, Johannesson B, et al. The ENaC-overexpressing mouse as a model of cystic fibrosis lung disease. J Cyst Fibros 2011; 10 Suppl 2: S172-S182.
11. Grubb BR, O'Neal WK, Ostrowski LE, Kreda SM, Button B, Boucher RC. Transgenic hCFTR expression fails to correct beta-ENaC mouse lung disease. Am J Physiol Lung Cell Mol Physiol 2012; 302(2): L238-L247.
12. Gruenert DC, Willems M, Cassiman JJ, Frizzell RA. Established cell lines used in cystic fibrosis research. J Cyst Fibros 2004; 3 Suppl 2: 191-6.
13. Cozens AL, Yezzi MJ, Kunzelmann K, et al. CFTR expression and chloride secretion in polarized immortal human bronchial epithelial cell. Am J Respir Cell Mol Biol 1994; 10: 38-47.
14. Sobczak K, Segal A, Bangel-Ruland N, et al. Specific inhibition of epithelial Na+ channels by antisense oligonucleotides for the treatment of Na+ hyperabsorption in cystic fibrosis. J Gene Med 2009; 11(9): 813-23.
15. Briel M, Greger R, Kunzelmann K. Cl-transport by cystic fibrosis transmembrane conductance regulator (CFTR) contributes to the inhibition of epithelial Na+ channels (ENaCs) in Xenopus oocytes co-expressing CFTR and ENaC. J Physiol (Lond) 1998; 508: 825-36.
16. Chabot H, Vives MF, Dagenais A, Grygorczyk C, Berthiaume Y, Grygorczyk R. Downregulation of epithelial sodium channel (ENaC) by CFTR co-expressing in Xenopus oocytes is independent of Cl-conductance. J Membr Biol 1999; 169: 175-88.
17. Nagel G, Szellas T, Riordan JR, Friedrich T, Hartung K. Nonspecific activation of the epithelial sodium channel by the CFTR chloride channel. EMBO rep 2001; 2: 249-54.
18. Chabot H, Vives MF, Dagenais A, Grygorczyk C, Berthiaume Y, Grygorczyk R. Downregulation of epithelial sodium channel (ENaC) by CFTR co-expressing in Xenopus oocytes is independent of Cl-conductance -Erratum. J Membr Biol 2002; 186: 185.
19. Segal A, Cucu D, Van Driessche W, Weber W-M. Rat ENaC expressed in Xenopus laevis oocytes is activated by cAMP and blocked Ni2+. FEBS Lett 2002; 515: 132-8.
20. Nagel G, Barbry P, Chabot H, Brochiero E, Hartung K, Grygorczyk R. CFTR fails to inhibit the epithelial sodium channel ENaC expressed in Xenopus laevis oocytes. J Physiol 2005; 564(Pt 3): 671-82.
21. Thibodeau PH, Butterworth MB. Proteases, cystic fibrosis and the epithelial sodium channel (ENaC). Cell Tissue Res 2013; 351(2): 309-23.
22. Ishikawa T, Jiang C, Stutts MJ, Marunaka Y, Rotin D. Regulation of the epithelial Na+ channel by cytosolic ATP. J Biol Chem 2003; 278(40): 38276-86.
23. Kashlan OB, Kleyman TR. Epithelial Na(+) channel regulation by cytoplasmic and extracellular factors. Exp Cell Res 2012; 318(9): 1011-9.
24. Enuka Y, Hanukoglu I, Edelheit O, Vaknine H, Hanukoglu A. Epithelial sodium channels (ENaC) are uniformly distributed on motile cilia in the oviduct and the respiratory airways. Histochem Cell Biol 2012; 137(3): 339-53.
25. Gaillard EA, Kota P, Gentzsch M, Dokholyan NV, Stutts MJ, Tarran R. Regulation of the epithelial Na+ channel and airway surface liquid volume by serine proteases. Pflugers Arch 2010; 460(1): 1-17.
26. Gentzsch M, Dang H, Dang Y, et al. The cystic fibrosis transmembrane conductance regulator impedes proteolytic stimulation of the epithelial Na+ channel. J Biol Chem 2010; 285(42): 32227-32.
27. Canessa CM, Schild L, Buell G, et al. Amiloride-sensitive epithelial Na+ channel is made of three homologous subunits. Nature 1994; 367: 463-7.
28. Alvarez de la Rosa D, Canessa CM, Fyfe GK, Zhang P. Structure and regulation of amiloride-sensitive sodium channels. Annu Rev Physiol 2000; 62: 573-94.
29. Kellenberger S, Schild L. Epithelial sodium channel/degenerin family of ion channels: a variety of functions for a shared structure. Phys Rev 2002; 82: 735-67.
30. Jasti J, Furukawa H, Gonzales EB, Gouaux E. Structure of acidsensing ion channel 1 at 1.9 A resolution and low pH. Nature 2007; 449(7160): 316-23.
31. Stockand JD, Staruschenko A, Pochynyuk O, Booth RE, Silverthorn DU. Insight toward epithelial Na+ channel mechanism revealed by the acid-sensing ion channel 1 structure. IUBMB Life 2008; 60(9): 620-8.
32. Waldmann R, Champigny G, Bassilana F, Voilley N, Lazdunski M. Molecular cloning and functional expression of a novel amiloridesensitive Na+ channel. J Biol Chem 1995; 270: 27411-4.
33. Ji HL, Zhao RZ, Chen ZX, Shetty S, Idell S, Matalon S. delta ENaC: a novel divergent amiloride-inhibitable sodium channel. Am J Physiol Lung Cell Mol Physiol 2012; 303(12): L1013-L1026.
34. Giraldez T, Rojas P, Jou J, Flores C, Alvarez dlR. The epithelial sodium channel delta-subunit: new notes for an old song. Am J Physiol Renal Physiol 2012; 303(3): F328-F338.
35. Zhao RZ, Nie HG, Su XF, et al. Characterization of a novel splice variant of delta ENaC subunit in human lungs. Am J Physiol Lung Cell Mol Physiol 2012; 302(12): L1262-L1272.
36. Bangel-Ruland N, Sobczak K, Christmann T, et al. Characterization of the epithelial sodium channel delta-subunit in human nasal epithelium. Am J Respir Cell Mol Biol 2010; 42(4): 498-505.
37. Althaus M. ENaC inhibitors and airway re-hydration in cystic fibrosis: state of the art. Curr Mol Pharmacol 2013; 6(1): 3-12.
38. Kleyman TR, Cragoe EJ. Amiloride and its analogs as tools in the study of ion transport. J Membr Biol 1988; 105: 1-21.
39. Kohler D, App E, Schmitz-Schumann M, Wurtemberger G, Matthys H. Inhalation of amiloride improves the mucociliary and the cough clearance in patients with cystic fibroses. Eur J Respir Dis Suppl 1986; 146: 319-26.
40. App EM, King M, Helfesrieder R, Kohler D, Matthys H. Acute and long-term amiloride inhalation in cystic fibrosis lung disease. A rational approach to cystic fibrosis therapy. Am Rev Respir Dis 1990; 141(3): 605-12.
41. Hofmann T, Senier I, Bittner P, Huls G, Schwandt HJ, Lindemann H. Aerosolized amiloride: dose effect on nasal bioelectric properties, pharmacokinetics, and effect on sputum expectoration in patients with cystic fibrosis. J Aerosol Med 1997; 10(2): 147-58.
42. Knowles MR, Church NL, Waltner WE, et al. A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N Engl J Med 1990; 322(17): 1189-94.
43. Graham A, Hasani A, Alton EW, et al. No added benefit from nebulized amiloride in patients with cystic fibrosis. Eur Respir J 1993; 6(9): 1243-8.
44. Tomkiewicz RP, App EM, Zayas JG, et al. Amiloride inhalation therapy in Cystic fibrosis. Am Rev Respir Dis 1993; 148: 1002-7.
45. Hirsh AJ, Sabater JR, Zamurs A, et al. Evaluation of second generation amiloride analogs as therapy for cystic fibrosis lung disease. J Pharmacol Exp Ther 2004; 311(3): 929-38.
46. Hofmann T, Stutts MJ, Ziersch A, et al. Effects of topically delivered benzamil and amiloride on nasal potential difference and sodium absorption in cystic fibrosis respiratory epithelium. Am J Respir Crit Care Med 1998; 157: 1844-9.
47. Burrows EF, Southern KW, Noone PG. Sodium channel blockers for cystic fibrosis. Cochrane Database Syst Rev 2012; 3: CD005087.
48. Zhou Z, Treis D, Schubert SC, et al. Preventive but not late amiloride therapy reduces morbidity and mortality of lung disease in betaENaC-overexpressing mice. Am J Respir Crit Care Med 2008; 178(12): 1245-56.
49. Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 2010; 50: 259-93.
50. Akhtar S. Antisense technology: selection and delivery of optimally acting antisense oligonucleotides. J Drug Target 1998; 5(4): 225-34.
51. Southwell AL, Skotte NH, Bennett CF, Hayden MR. Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases. Trends Mol Med 2012; 18(11): 634-43.
52. Hummler E, Barker P, Gatzy J, et al. Early death due to defective neonatal lung liquid clearance in alpha-ENaC-deficient mice. Nat Genet 1996; 12(3): 325-8.
53. Hummler E, Merillat AM, Rubera I, Rossier BC, Beermann F. Conditional gene targeting of the Scnn1a (alphaENaC) gene locus. Genesis 2002; 32(2): 169-72.
54. Jain L, Chen XJ, Malik B, Al-Khalili O, Eaton DC. Antisense oligonucleotides against the alpha-subunit of ENaC decrease lung epithelial cation-channel activity. Am J Physiol 1999; 276(6 Pt 1): L1046-L1051.
55. Castanotto D, Rossi JJ. The promises and pitfalls of RNAinterference-based therapeutics. Nature 2009; 457(7228): 426-33.
56. Haussecker D. The Business of RNAi Therapeutics in 2012. Mol Ther Nucleic Acids 2012; 1: e8.
57. Burnett JC, Rossi JJ. RNA-based therapeutics: current progress and future prospects. Chem Biol 2012; 19(1): 60-71.
58. Caci E, Melani R, Pedemonte N, et al. Epithelial sodium channel inhibition in primary human bronchial epithelia by transfected siRNA. Am J Respir Cell Mol Biol 2009; 40(2): 211-6.
59. Gianotti A, Melani R, Caci E, et al. Epithelial sodium channel silencing as a strategy to correct the airway surface fluid deficit in cystic fibrosis. Am J Respir Cell Mol Biol 2013; 49(3): 445-52.
60. Clark KL, Hughes SA, Bulsara P, et al. Pharmacological Characterization of a Novel ENaCalpha siRNA (GSK2225745) With Potential for the Treatment of Cystic Fibrosis. Mol Ther Nucleic Acids 2013; 2: e65.
61. Ghatak S, Hascall VC, Berger FG, et al. Tissue-specific shRNA delivery: a novel approach for gene therapy in cancer. Connect Tissue Res 2008; 49(3): 265-9.
62. Burnett JC, Rossi JJ, Tiemann K. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J 2011; 6(9): 1130-46.
63. Ramachandran S, Karp PH, Osterhaus SR, et al. Posttranscriptional regulation of cystic fibrosis transmembrane conductance regulator expression and function by microRNAs. Am J Respir Cell Mol Biol 2013; 49(4): 544-51.
64. McKiernan PJ, Cunningham O, Greene CM, Cryan SA. Targeting miRNA-based medicines to cystic fibrosis airway epithelial cells using nanotechnology. Int J Nanomedicine 2013; 8: 3907-15.
65. Wagner RW. Gene inhibition using antisense oligodeoxynucleotides. Nature 1994 Nov 24; 372(6504): 333-5.
66. Merkel OM, Rubinstein I, Kissel T. siRNA Delivery to the lung: What's new? Adv Drug Deliv Rev 2014; 75C: 112-28.
67. Gill DR, Hyde SC. Delivery of genes into the CF airway. Thorax 2014; 69(10): 962-4.
68. Armstrong DK, Cunningham S, Davies JC, Alton EW. Gene therapy in cystic fibrosis. Arch Dis Child 2014; 99(5): 465-8.
69. Cheng SH, Gregory RJ, Marshall J, et al. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 1990; 63: 827-34.
70. Leier G, Bangel-Ruland N, Sobczak K, Knieper Y, Weber WM. Sildenafil acts as potentiator and corrector of CFTR but might be not suitable for the treatment of CF lung disease. Cell Physiol Biochem 2012; 29(5-6): 775-90.
71. Bangel-Ruland N, Tomczak K, Fernandez FE, et al. Cystic fibrosis transmembrane conductance regulator-mRNA delivery: a novel alternative for cystic fibrosis gene therapy. J Gene Med 2013; 15(11-12): 414-26.
72. Mall MA, Graeber SY, Stahl M, Zhou-Suckow Z. Early cystic fibrosis lung disease: Role of airway surface dehydration and lessons from preventive rehydration therapies in mice. Int J Biochem Cell Biol 2014; 52: 174-9.